Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib + binimetinib in Chinese patients with BRAF V600E-mutant metastatic NSCLC
CTR20212962Phase 2Active
- Sponsor
- Pierre Fabre Laboratories
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of encorafenib, binimetinib in non-small cell lung cancer (NSCLC), sponsored by Pierre Fabre Laboratories. Started Jun 2022; status: active.
02
Drugs
encorafenibbinimetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20212962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212962.